Table 3. Clinical features according to anti-NT5C1Aautoantibody status.
| Ever present | ||||
|---|---|---|---|---|
|
| ||||
| Anti-NT5C1A Ab+ (n=102) | Anti-NT5C1A Ab - (n=278) | univariate p-value | multivariate p-value | |
|
| ||||
| Muscle involvement | ||||
| Proximal weakness | 99% (101/102) | 100% (277/278) | 0.5 | 0.6 |
| Distal weakness | 50% (51/101) | 45% (122/271) | 0.3 | 0.4 |
| Muscle atrophy | 35% (36/102) | 38% (105/274) | 0.6 | 0.8 |
| Myalgia | 66% (67/101) | 63% (172/271) | 0.6 | 0.5 |
| Falling | 44% (45/102) | 45% (122/274) | 0.9 | 0.8 |
| Dysphonia | 40% (40/101) | 29% (80/275) | 0.05 | 0.2 |
| Lung involvement | ||||
| Interstitial lung disease | 13% (13/102) | 7% (20/276) | 0.09 | 0.06 |
| Dyspnea on exertion | 35% (36/102) | 27% (74/273) | 0.1 | 0.2 |
| Joint involvement | ||||
| Arthritis | 57% (58/102) | 49% (137/277) | 0.2 | 0.5 |
| Arthralgia | 66% (67/102) | 64% (177/276) | 0.8 | 0.7 |
| Joint contractures | 68% (69/102) | 57% (159/277) | 0.07 | 0.4 |
| Skin involvement | ||||
| Heliotrope rash | 84% (85/101) | 77% (214/277) | 0.1 | 0.6 |
| Gottron's papules | 87% (89/102) | 81% (223/277) | 0.1 | 0.5 |
| Calcinosis | 27% (28/102) | 31% (86/278) | 0.5 | 0.5 |
| Raynaud's phenomenon | 17% (17/102) | 14% (39/276) | 0.5 | 0.03 |
| Mechanic's hands | 9% (9/100) | 7% (18/275) | 0.4 | 0.2 |
| V or Shawl sign rash | 43% (44/102) | 26% (72/276) | 0.001 | 0.02 |
| Malar rash | 81% (83/102) | 66% (184/278) | 0.004 | 0.1 |
| Photosensitivity | 62% (61/99) | 43% (116/272) | 0.001 | 0.09 |
| Linear extensor erythema | 42% (42/101) | 34% (91/271) | 0.2 | 0.5 |
| Gastrointestinal involvement | ||||
| Dysphagia | 44% (45/102) | 39% (109/277) | 0.4 | 0.5 |
| Regurgitation | 25% (26/102) | 19% (52/277) | 0.2 | 0.4 |
| Systemic involvement | ||||
| Weight loss | 44% (44/101) | 42% (115/277) | 0.7 | 0.9 |
| Fever | 30% (30/100) | 31% (83/267) | 0.8 | 0.6 |
| Early symptom scores | 0.27 (0.12) | 0.23 (0.11) | 0.005 | 0.1 |
| Total | ||||
| Muscle | 0.38 (0.19) | 0.38 (0.20) | 0.8 | 0.9 |
| Joint | 0.52 (0.41) | 0.43 (0.42) | 0.06 | 0.4 |
| Cutaneous | 0.29 (0.15) | 0.24 (0.13) | 0.002 | 0.3 |
| Gastrointestinal | 0.09 (0.13) | 0.07 (0.10) | 0.03 | 0.06 |
| Pulmonary | 0.13 (0.17) | 0.08 (0.15) | 0.004 | 0.005 |
| Cardiac | 0.03 (0.08) | 0.03 (0.08) | 0.8 | 0.6 |
| Constitutional | 0.41 (0.26) | 0.39 (0.27) | 0.4 | 0.8 |
Abbreviations: NT5C1A, cytosolic 5′-nucleotidase 1A; Ab, autoantibody. Dichotomous variables were represented as percentage (count/total), continuous variables as mean (SD) and the creatine kinase was presented as median (Q1-Q3).